MA60467B1 - Composition de rapamycine - Google Patents
Composition de rapamycineInfo
- Publication number
- MA60467B1 MA60467B1 MA60467A MA60467A MA60467B1 MA 60467 B1 MA60467 B1 MA 60467B1 MA 60467 A MA60467 A MA 60467A MA 60467 A MA60467 A MA 60467A MA 60467 B1 MA60467 B1 MA 60467B1
- Authority
- MA
- Morocco
- Prior art keywords
- rapamycin
- composition
- glyceryl
- monomyristin
- monolaurin
- Prior art date
Links
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 4
- 229960002930 sirolimus Drugs 0.000 title abstract 4
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 abstract 3
- DCBSHORRWZKAKO-UHFFFAOYSA-N rac-1-monomyristoylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(O)CO DCBSHORRWZKAKO-UHFFFAOYSA-N 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000002144 chemical decomposition reaction Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940068939 glyceryl monolaurate Drugs 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La rapamycine est une substance thérapeutique médicalement connue. Un problème avec la rapamycine est qu'elle est assez instable et sujette à une dégradation chimique pendant le stockage. Ceci peut conduire à un médicament devenant "insuffisamment fort" pendant sa durée de conservation. Un objet de l'invention est de remédier au moins en partie à ce problème. L'invention concerne une composition pour traitement topique, comprenant de la rapamycine en tant que principe actif ; un véhicule comprenant de la monolaurine, par exemple sous forme de monolaurate de glycéryle et de la monomyristine, par exemple en tant que monomyristate de glycéryle ; et de l'eau en tant que solvant.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020277132A AU2020277132B1 (en) | 2020-11-24 | 2020-11-24 | A Rapamycin Composition |
| PCT/NZ2021/050194 WO2022114964A1 (fr) | 2020-11-24 | 2021-11-04 | Composition de rapamycine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA60467A1 MA60467A1 (fr) | 2023-08-31 |
| MA60467B1 true MA60467B1 (fr) | 2024-11-29 |
Family
ID=78476632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA60467A MA60467B1 (fr) | 2020-11-24 | 2021-11-04 | Composition de rapamycine |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20240108606A1 (fr) |
| EP (1) | EP4251151A4 (fr) |
| JP (1) | JP2023550472A (fr) |
| KR (1) | KR20230112677A (fr) |
| CN (1) | CN116528905A (fr) |
| AU (1) | AU2020277132B1 (fr) |
| CA (1) | CA3196588A1 (fr) |
| CO (1) | CO2023007684A2 (fr) |
| CR (1) | CR20230284A (fr) |
| EC (1) | ECSP23040785A (fr) |
| GB (1) | GB2615048B (fr) |
| IL (1) | IL302475A (fr) |
| MA (1) | MA60467B1 (fr) |
| MX (1) | MX2023005980A (fr) |
| PE (1) | PE20240818A1 (fr) |
| TW (1) | TW202237094A (fr) |
| WO (1) | WO2022114964A1 (fr) |
| ZA (1) | ZA202305222B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023203871B1 (en) * | 2023-06-20 | 2024-07-25 | Aft Pharmaceuticals Ltd | A Rapamycin Method of Treatment and Composition |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015121836A1 (fr) * | 2014-02-14 | 2015-08-20 | Druggability Technologies Ip Holdco Limited | Complexes de sirolimus et leur dérivés, leur procédé de préparation et compositions pharmaceutiques les contenant |
| WO2020172266A1 (fr) * | 2019-02-20 | 2020-08-27 | AI Therapeutics, Inc. | Formulations topiques de rapamycine et leur utilisation dans le traitement d'angiofibromes faciaux et d'autres troubles cutanés |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| JPS62266135A (ja) * | 1986-05-12 | 1987-11-18 | Pola Chem Ind Inc | 水中油型乳化組成物 |
| GB9723669D0 (en) * | 1997-11-07 | 1998-01-07 | Univ Aberdeen | Skin penetration enhancing components |
| US7026374B2 (en) * | 2002-06-25 | 2006-04-11 | Aruna Nathan | Injectable microdispersions for medical applications |
| EP1981477A1 (fr) * | 2006-02-02 | 2008-10-22 | Leo Pharma A/S | Composition topique comprenant une substance antibactérienne |
| US9308181B2 (en) * | 2006-03-06 | 2016-04-12 | Nuvo Research Inc. | Topical formulations, systems and methods |
| US20080276935A1 (en) * | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
| US20140094484A1 (en) * | 2012-10-02 | 2014-04-03 | Qlt Inc. | Sustained delivery formulations of rapamycin compounds |
| DE102013224627A1 (de) * | 2013-11-29 | 2015-06-03 | Andreas Lauterbach | Pharmazeutische Formulierung mit Lipidmikropartikeln und Herstellungsverfahren |
| RS64482B1 (sr) * | 2014-04-04 | 2023-09-29 | Ai Therapeutics Inc | Inhalaciona formulacija rapamicina za lečenje stanja povezanih sa starenjem |
| CN118236560A (zh) * | 2015-04-24 | 2024-06-25 | 优敦力公司 | 用于非血管狭窄的药物涂布的球囊导管 |
| KR20180081501A (ko) * | 2015-09-24 | 2018-07-16 | 드렉셀유니버시티 | 진피 장애를 치료하거나 예방하는 신규한 조성물 및 방법 |
| CA3032473A1 (fr) * | 2016-08-10 | 2018-02-15 | The Board Of Regents Of The University Of Texas System | Therapie a base de rapamycine topique |
| KR20210087929A (ko) * | 2018-08-30 | 2021-07-13 | 케미스트리알엑스. | 시롤리무스 함유 조성물 |
-
2020
- 2020-11-24 AU AU2020277132A patent/AU2020277132B1/en active Active
-
2021
- 2021-10-19 TW TW110138730A patent/TW202237094A/zh unknown
- 2021-11-04 GB GB2306544.4A patent/GB2615048B/en active Active
- 2021-11-04 MX MX2023005980A patent/MX2023005980A/es unknown
- 2021-11-04 US US18/038,409 patent/US20240108606A1/en active Pending
- 2021-11-04 CA CA3196588A patent/CA3196588A1/fr active Pending
- 2021-11-04 PE PE2023001672A patent/PE20240818A1/es unknown
- 2021-11-04 EP EP21898774.1A patent/EP4251151A4/fr active Pending
- 2021-11-04 MA MA60467A patent/MA60467B1/fr unknown
- 2021-11-04 IL IL302475A patent/IL302475A/en unknown
- 2021-11-04 CR CR20230284A patent/CR20230284A/es unknown
- 2021-11-04 CN CN202180077636.4A patent/CN116528905A/zh active Pending
- 2021-11-04 WO PCT/NZ2021/050194 patent/WO2022114964A1/fr not_active Ceased
- 2021-11-04 JP JP2023530780A patent/JP2023550472A/ja active Pending
- 2021-11-04 KR KR1020237021011A patent/KR20230112677A/ko active Pending
-
2023
- 2023-05-11 ZA ZA2023/05222A patent/ZA202305222B/en unknown
- 2023-06-01 EC ECSENADI202340785A patent/ECSP23040785A/es unknown
- 2023-06-13 CO CONC2023/0007684A patent/CO2023007684A2/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015121836A1 (fr) * | 2014-02-14 | 2015-08-20 | Druggability Technologies Ip Holdco Limited | Complexes de sirolimus et leur dérivés, leur procédé de préparation et compositions pharmaceutiques les contenant |
| WO2020172266A1 (fr) * | 2019-02-20 | 2020-08-27 | AI Therapeutics, Inc. | Formulations topiques de rapamycine et leur utilisation dans le traitement d'angiofibromes faciaux et d'autres troubles cutanés |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202305222B (en) | 2024-10-30 |
| US20240108606A1 (en) | 2024-04-04 |
| EP4251151A1 (fr) | 2023-10-04 |
| AU2020277132B1 (en) | 2021-11-04 |
| TW202237094A (zh) | 2022-10-01 |
| JP2023550472A (ja) | 2023-12-01 |
| CR20230284A (es) | 2023-08-07 |
| CA3196588A1 (fr) | 2022-06-02 |
| PE20240818A1 (es) | 2024-04-18 |
| GB2615048A (en) | 2023-07-26 |
| EP4251151A4 (fr) | 2024-10-16 |
| KR20230112677A (ko) | 2023-07-27 |
| CN116528905A (zh) | 2023-08-01 |
| CO2023007684A2 (es) | 2023-07-21 |
| ECSP23040785A (es) | 2023-07-31 |
| IL302475A (en) | 2023-06-01 |
| GB202306544D0 (en) | 2023-06-14 |
| WO2022114964A1 (fr) | 2022-06-02 |
| MX2023005980A (es) | 2023-06-07 |
| MA60467A1 (fr) | 2023-08-31 |
| GB2615048B (en) | 2025-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2006339842B2 (en) | Pharmaceutical composition for external use | |
| Mueller et al. | A review of topical therapy for skin infections with bacteria and yeast | |
| CA2645110C (fr) | Composition pharmaceutique pour usage externe | |
| CA2492976A1 (fr) | Solution destinee a une application ungueale et peri-ungueale | |
| EP2983678B1 (fr) | Composition antimicrobienne | |
| CA2883613C (fr) | Composition pharmaceutique de traitement d'infections fongiques | |
| RU2010123052A (ru) | Авенантрамидсодержащие композиции | |
| JP2003514875A (ja) | 創傷治癒を改善し、薬を投与するためのプロペラント不要のスプレー式皮膚パッチ組成物 | |
| US6150381A (en) | Methods of treating microbial infection and therapeutic formulations therefor | |
| US8012173B2 (en) | Surgical suture material with an antimicrobial surface and process for providing an antimicrobial coating on surgical suture material | |
| DE50112452D1 (de) | Transdermales therapeutisches system zur behandlung des restless-legs-syndroms | |
| RU2008114352A (ru) | Композиции для местного применения | |
| MX9400800A (es) | Un complejo de estabilizacion neutro para ci-979 hci, un activador de la cognicion. | |
| ZA202305222B (en) | A rapamycin composition | |
| AR046146A1 (es) | Formulaciones farmaceuticas transdermicas para pulverizacion que comprenden un agente activo, un copolimero de vp/va y un vehiculo no acuoso | |
| UA49789C2 (uk) | Застосування димеру лізоциму як лікарського засобу для інгібування біосинтезу фактора некрозу пухлини, спосіб лікування та профілактики захворювань (варіанти), фармацевтична композиція (варіанти), застосування димеру лізоциму як лікарського засобу для профілактики або лікування сніду | |
| CA2436414A1 (fr) | Composition a usage dermatologique et veterinaire | |
| WO2003026710A1 (fr) | Melange a utiliser comme pansement protecteur | |
| MX2025013949A (es) | Un metodo de tratamiento y composicion con rapamicina | |
| ES2456115T3 (es) | Composición propelente presurizada sustancialmente exenta de agua | |
| WO2009084975A8 (fr) | Composition présentant une haute activité osmotique antimicrobienne, anti-inflammatoire et régénérante | |
| FR2566270A1 (fr) | Formes pharmaceutiques sous forme de gel, pour l'application topique de principes actifs | |
| EA200400910A1 (ru) | Композиция противовоспалительного, регенерационного и антимикробного действия | |
| AR132433A1 (es) | Derivados de imidazotriazina como moduladores de il-17 | |
| HK40020735B (en) | Tyrothricin for use in the treatment or prophylaxis of body odour and preparations therefor |